ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

 

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy
S

Impact of Kinase Domain Mutations on Second Line Nilotinib Therapy In CML Chronic Phase – Real World Data from a Developing Country Perspective

By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Shinto Francis Thekkudan
By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Shinto Francis Thekkudan
6 views
November 16, 2018
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
Brief Oral Communications (Biology)
05:24
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Impact of Kinase Domain Mutations on Second Line Nilotinib Therapy I…

Feat. S. Thekkudan
08:46
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Aberrant Methylation in Promoter Regions of CpG Islands of Multiple …

Feat. S. Guru